.jpg "DSC09286(2).jpg")
CHAMEDITECH (CEO Sok-jin Kim), a subsidiary of Cha Biotech, has launched the HA (hyaluronic acid) filler ‘HyaFilia’ in China, and has begun to enter the global market in earnest.
CHAMEDITECH completed local clinical trials in China and obtained product approval from the National Medical Products Administration (NMPA) in September 2024. HyaFilia will sign a supply contract with a local cosmetic and plastic surgery medical device company and begin full-scale sales.
To commemorate the launch of HyaFilia in China, CHAMEDITECH held a launching event at the Four Seasons Hotel in Guangzhou, China on the 26th December, attended by approximately 60 people including CEO Sok-jin Kim of CHAMEDITECH, local distributors, and medical staff from Korea and China.
.png "EOS72170-horz(1).png")
On this day, Dr. Ik-soo Koh, a plastic surgery specialist, attended the event as a lecturer and gave a lecture on the topic of ‘Introduction of HYAFILIA products based on CHA-HEART technology’. His lecture was about the excellence of HA filler HyaFilia, which is consist of chemically and physically cross-linked HA so does not produce toxic residues, and successful treatment cases using HyaFilia. An event was also held that CEO Sok-jin Kim awarded local distribution rights to overseas distributors.
China is rapidly increasing demand for fillers due to increasing interest in beauty and rising income levels in major cities such as Beijing and Shanghai. According to a report by KOTRA Shanghai Trade Center, the market size of China’s hyaluronic acid filler products increased from 3.1 billion yuan (approximately 613.3 billion won) in 2017 to 6.4 billion yuan (approximately 1.2663 trillion won) in 2021, and is expected to reach 44.1 billion yuan (approximately 8.7256 trillion won) in 2030.
CHAMEDITECH is advancing into the aesthetic markets of key countries on each continent with HyaFilia as its main product. In January of this year, CHAMEDITECH entered Thailand, which has a large share of the Southeast Asian beauty market, and in the second half of the year, entered Brazil, the largest country in South America.
.JPG "EOS72802(1).JPG")
'HyaFilia' is a hyaluronic acid filler developed by CHAMEDITECH, and it is a product that has established its position in overseas markets by exporting to Europe, the Middle East, etc. Based on their own 'CHA-HEART' technology, CHAMEDITECH minimized the chemical cross-linking agent BDDE (ButanDiol Diglycidyl Ether) to reduce the risk of cytotoxicity and increase safety.
CHAMEDITECH CEO Sok-jin Kim said, "We plan to continuously discover local partners in the global market and expand our position," and "Based on our excellent product capabilities and technology, we will quickly expand the market share of CHAMEDITECH's filler brand, HyaFilia, in the global market."